CXCR4-targeted Therapy Inhibits VEGF Expression and Chondrosarcoma Angiogenesis and Metastasis

Xiaojuan Sun¹, Cherie Charbonneau¹, Lei Wei¹, Wentian Yang¹, Qian Chen¹, Richard M. Terek¹,²

¹ Department of Orthopaedics, Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence RI, USA
² Surgical Service, Department of Veterans Affairs Medical Center, Providence RI, USA

Running title: CXCR4-targeted Therapy for Chondrosarcoma

Key words: bone cancer, cartilage tumor

Abbreviations list: CXCR4: CHEMOKINE (C-X-C MOTIF) RECEPTOR 4, VEGFA: VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUVEC: human umbilical vein endothelial cell, HIF1: HYPOXIA-INDUCING FACTOR 1, MMPs: MATRIX METALLOPEPTIDASES, CXCL12: CHEMOKINE (C-X-C MOTIF) LIGAND 12

Notes

Financial Support: One or more of the authors have received funding from the National Institutes of Health and from the National Center for Research Resources, a component of NIH: R.M.Terek, Q. Chen (Grant 1P20RR024484-01 and 9P20GM104937-06), L. Wei (Grant R01AR059142), W. Yang (Grant R21AR57156).

Corresponding Author:
R. M. Terek
Orthopaedic Oncology Laboratory, Coro West Building, Room 402B, 1 Hoppin St, Providence, RI 02903, USA
401-457-1555
401-831-8992 (fax)
email: Richard_Terek@Brown.edu

The authors have no conflicts of interest to report.
Abstract

Chondrosarcoma is notable for its lack of response to conventional cytotoxic chemotherapy, propensity for developing lung metastases, and poor survival. Therefore, a better understanding of angiogenic and metastatic pathways is needed. Multiple pathways regulate angiogenesis and metastasis, including chemokines and their receptors. In this study, we investigated CHEMOKINE (C-X-C MOTIF) RECEPTOR 4 (CXCR4) signaling in chondrosarcoma and tested the hypotheses that CXCR4 inhibition suppresses tumor angiogenesis and metastasis. CXCR4 expression, analyzed by real-time PCR and Western blot, was increased in human chondrosarcoma cell line JJ compared to normal chondrocytes, and was further increased in JJ by hypoxia (2% O2), VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGFA) (10ng/ml), and in xenograft tumors in nude mice. The CXCR4 ligand CHEMOKINE (C-X-C MOTIF) LIGAND 12 (CXCL12) (10 ng/ml) doubled secreted VEGFA, measured with ELISA, under hypoxic conditions and this conditioned media increased HUVEC tube formation. These effects were inhibited by CXCR4 siRNA or AMD3100 (5 µg/mL). In a xenograft mouse model, four weeks of AMD3100 treatment (1.25 mg/kg, ip, bid) inhibited tumor angiogenesis, tumor growth, and metastasis. VEGFA content in tumor extracts was decreased (7.19 ± 0.52 ng/mL control vs. 3.96 ± 0.66 treatment) and bioimaging of angiogenesis was decreased by 56%. Tumor volumes averaged 4.44 ± 0.68 cm³ in control compared to 2.48 ± 0.61 cm³ in the treatment group. The number of lung metastatic nodules was 23 ± 9 in control compared to 10 ± 6 in the treatment group (N=8/group). Therefore, CXCR4 targeted therapy may be a treatment strategy for chondrosarcoma.
Introduction

Chondrosarcoma is a devastating disease without effective systemic treatment. It is the second most common primary malignant bone tumor in large epidemiologic series(1). Five-year survival of patients with this cancer is 10% to 25% and there has been no progress over the last several decades (2;3). The consensus is that conventional cytotoxic chemotherapy does not improve survival(4). Patients with chondrosarcoma typically succumb to pulmonary metastases. Angiogenesis is necessary for both tumor growth and metastasis (5;6). Virtually all of the research on tumor vascularity and the factors that stimulate angiogenesis have shown correlations between vascularity, expression of proangiogenic factors, biologic aggressiveness, high pathologic grade, and poor survival(7). We found grade II and III chondrosarcomas have more microvasculature than benign or grade I tumors (8). Microvasculature correlates with clinical behavior, since it is primarily grade II and III chondrosarcomas that metastasize (9). Thus, chondrosarcoma development may be linked to angiogenesis.

The angiogenic switch typically involves hypoxia and oncogenes as activators of expression of the primary proangiogenic factor VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGFA) (6). We have shown grade II and III chondrosarcoma have higher expression of VEGFA and the major transcription factor related to hypoxia, HYPOXIA-INDUCING FACTOR 1 (HIF1) (10). In addition to VEGFA, MATRIX METALLOPEPTIDASES (MMPs) are factors related to angiogenesis and metastatic behavior and MMP1 expression in chondrosarcoma is inversely correlated with survival(11). Directly blocking expression of these factors in vivo is not yet feasible and our understanding of the regulation of these factors in chondrosarcoma is incomplete.
Pathways related to angiogenesis and metastasis could involve chemokines and their receptors. There are four groups of chemokine receptors: C, CC, CXC, and CX3C. Under normal circumstances they are important in immune cell function and migration of stem cells to sites of injury; however, in cancer, they regulate invasion, angiogenesis, migration, and metastasis. CHEMOKINE (C-X-C MOTIF) RECEPTOR 4 (CXCR4) is the chemokine receptor most commonly expressed in tumors (12). The ligand for CXCR4 is CHEMOKINE (C-X-C MOTIF) LIGAND 12 (CXCL12) (13;14). CXCR4 and CXCL12 together promote metastasis in some tumors by mediating proliferation and migration of tumor cells and enhancing tumor-associated angiogenesis (15-17). CXCR4 is a transmembrane G-protein-coupled receptor, whose activation also leads to intracellular signaling cascades, downstream targets of which include MMP1 and VEGFA (17;18). The increased expression of chemokine receptors has been mostly investigated in carcinomas (19-22). We (23) and others (24) have found CXCR4 is overexpressed in chondrosarcoma cells and primary chondrosarcoma tissue, and we have also shown that one mechanism of increased CXCR4 expression is hypoxia, specifically HIF1 (23). VEGFA has also been shown to upregulate CXCR4 expression in endothelial cells, and in some, but not all tumor cells (25;26). Development of agents that block CXCR4 has been propelled by the fact that it is a coreceptor for HIV. The drug AMD3100 is a bicyclam (1,1’-[1,4-Phenylenebis-(methylene)]-bis-(1,4,8,11-tetraazacyclotetradecane) octahydrochloride) (27) with high specificity for CXCR4 and is the prototypical CXCR4-blocking drug (28). It is already approved for human use as a stem cell mobilizer. In chondrosarcoma cells, CXCR4 blockade with AMD3100 inhibits expression of MMP1 and invasion in vitro (23). CXCR4, therefore, is an attractive target
since it is the most common chemokine receptor expressed in cancer cells, upregulates factors related to invasiveness and angiogenesis in chondrosarcoma, and agents exist that can block this receptor. As an orphan disease, it is unlikely that novel agents will be developed for chondrosarcoma and repurposing the use of drugs approved for one use to the treatment of orphan diseases is an NIH priority (29). Thus, it is important to identify pathways and agents that may have applicability for chondrosarcoma treatment.

In this study, we (1) investigated another potential mechanism of CXCR4 overexpression in chondrosarcoma involving the mutual regulation of VEGFA and CXCR4 by each other, (2) tested the hypothesis that CXCR4 inhibition decreases VEGFA expression and angiogenesis in vitro and in vivo, and (3) tested the hypothesis that CXCR4 inhibition decreases metastasis.

**Material and Methods**

**Chondrosarcoma cell line**

The human chondrosarcoma cell line JJ, derived from a human Grade II chondrosarcoma (a gift from Dr. Joel Block, Rush Medical School, Chicago, IL, in 1999), was cultured in complete medium (40% Dulbecco’s Modified Eagle’s Medium, 40% Minimal Essential Medium, 20% F12) with 10% fetal bovine serum (30), in a humidified incubator under 5% CO₂ and ambient oxygen (20%) or hypoxia (2%) (31). CXCL12, VEGFA (R&D Systems, Minneapolis, MN), and/or AMD3100 (Sigma-Aldrich Co, St Louis, MO) were added to the medium as indicated. The cell line was authenticated using short tandem repeat (STR) profiling and was performed (ATCC, Manassas, VA) on the source cell line in 1999, 2007, and repeated in 2012. There is 94% similarity between the different time points, the cells are human, and there are no matches with any cell lines in the ATCC
data base. Normal human chondrocytes were isolated from articular cartilage obtained from tumor resections.

**siRNA**

CXCR4 knockdown with siRNA was performed by transfecting JJ cells with CXCR4 or control siRNA (Qiagen, Valencia, CA, USA) using the HiPerFect® transfection reagent (Qiagen).

**Quantitative real-time PCR analysis for mRNAs**

For quantification of mRNA, total RNA was isolated from chondrocytes, JJ cells, and xenograft mouse tumors using the RNAqueous® Kit (Ambion, Austin, TX, USA). SYBR real-time PCR was carried out using two-step real-time qRT-PCR (Qiagen) with normalization to 18S rRNA (18S). The primers used for VEGFA, CXCR4, and 18S were previously reported (23;31). 18S was used as an internal control since it is reportedly the optimal reference gene (32). The comparative threshold cycle (Ct) method, i.e., the $2^{-\Delta\Delta Ct}$ method, was used for the calculation of fold amplification (33). Each experiment was evaluated with three PCR reactions and each experiment was repeated three times, the sample size necessary to maintain power at 0.80 to detect a 50% decrease with an alpha of 0.025 (one-tailed t-test).

**Western Blot**

Cell lysates containing forty µg of protein were separated via SDS-PAGE (Bio-Rad, Hercules, CA). Western Blot analyses were performed as previously described with CXCR4 antibody (IMGNEX, San Diego, CA) and actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA)(34). Protein concentrations were determined using the Quick Start Bradford protein assay (Bio-Rad).
ELISA

Conditioned medium was obtained 72 hours after transfection or AMD3100 treatment. Soluble VEGF-165 was detected using VEGF Immunoassay kit (R&D Systems, Minneapolis, MN) according to manufacturer’s instructions (34). VEGF-165 levels were measured two times for each condition and with normalization to the number of cells at the end of the culture period. Each experiment was repeated three times. Twenty mg of xenograft tumor tissue in RIPA buffer containing proteinase inhibitors (Roche) was homogenized on ice using TissueRuptor (Qiagen). Tissue lysates were centrifuged at 14000 rpm for 30 min, supernatant saved at -80ºC for later use. VEGF-165 levels in xenograft tumor lysates were normalized to total protein.

HUVEC Angiogenesis Assay

Human umbilical vein endothelial cell (HUVEC) (ATCC, Manassas, VA) tube formation in three-dimensional BD Matrigel™ matrix (BD Biosciences, San Jose, CA) was determined after culture with conditioned medium from JJ cells transfected with control or anti-CXCR4 siRNA or treated with AMD3100. Tube formation was quantified by seeding HUVECs on BD Matrigel™ cultures at $5 \times 10^4$ cells/well, 96 well plates and culturing for one day after addition of conditioned medium. The entire well of HUVECs were photographed, the tubular structures traced, and total length/well measured using Elements software (Nikon, Inc, Melville, NY).

Mouse model, bioimaging, tumor growth, metastasis analysis
JJ cells (100 µl of 1 × 10⁶ cells) were mixed with 300 µL Matrigel™ (BD Biosciences, San Jose, CA) and injected subcutaneously in the back of eight nude mice per group (nu/nu 6-8 week old female, Charles River Laboratory, Wilmington, MA). Treatment with AMD3100 (1.25 mg/kg) or control (phosphate-buffered saline) twice daily intraperitoneally 5 days/week was started on Day 14. All animal studies were approved by the Institutional Animal Care and Use Committee at Rhode Island Hospital and were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. In vivo bioimaging of angiogenesis in xenograft tumors was performed with fluorescence molecular tomography (FMT) (PerkinElmer, Waltham, MA) using AngioSense® 750 (PerkinElmer), a probe with an excitation wavelength of 750 nm and an emission wavelength of 780 nm at the start and after 3 weeks of treatment. Fluorochrome concentration in the target was calculated from reconstructed images and expressed as femtomoles of fluorochrome per defined target volume (the primary tumor). Tumors were measured with calipers and volumes were calculated with the formula for a scalene ellipsoid: height × width × length × 0.52. Weight was determined after 4 weeks of treatment at the time of excision. Lungs were analyzed with microscopy after fixation in 10% formalin. Transverse sections were be made at 100µm intervals. H&E stained slides were scanned with an Aperio Scanscope (Aperio Technologies, Inc.). Metastatic burden was quantified as the number of nodules per lung (35).

**Immunohistochemistry**

Tissue sections were deparaffinized and blocked with 3% serum and then stained with anti-CD31 antibody (1:100 dilution) (SC-56; Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) using Vectastain® ABC kit (VECTOR Laboratories, Burlingame, CA, USA).
Antibody staining was visualized with peroxidase-conjugated anti-mouse antibody and counterstained with hematoxylin. A negative control was performed on each tumor tissue stained with mouse IgG. Immunostained slides were photographed with a Spot RT™ camera (Diagnostic Imaging, Sterling Heights, MI, USA) and Nikon E800 microscope at 200×.

**Statistical analysis**

Gene expression in multiple groups *in vitro* were compared using one-way ANOVA, followed by Bonferroni’s multiple comparison test. We determined differences in gene and protein expression *in vivo*, bioimaging, and tumor weight and volume between control and AMD3100 or CXCR4siRNA groups using Student’s t-test. Lung metastatic burden was compared using Mann-Whitney U test. (GraphPadPrism, v 5.03, GraphPad Software, Inc., San Diego, CA).

**Results**

While it is known that CXCR4 is upregulated in primary human chondrosarcoma, we evaluated CXCR4 expression in xenograft tumors to confirm the model could be used to study CXCR4 inhibition. CXCR4 was expressed at higher levels in JJ cells compared to normal chondrocytes, and expression was further increased (p < 0.001) by hypoxia 46-fold and in xenograft tumors 438-fold, both relative to chondrocytes. Western blot confirmed the results (Fig.1), suggesting CXCR4 may be a relevant treatment target.

JJ cells were treated with CXCL12 or VEGFA to evaluate if CXCR4 signaling regulates expression of VEGFA, if VEGFA regulates CXCR4, and if CXCR4 blockade would inhibit angiogenesis *in vitro*. CXCL12 during normoxia increased VEGFA mRNA
threefold (p < 0.03) (Fig. 2A). Similarly, CXCR4 mRNA increased fivefold (p < 0.02) after cells were treated with VEGFA (Fig. 2B). CXCL12 treatment during hypoxia increased VEGFA protein concentration in conditioned media (Figure 3A), HUVEC tube formation (Figure 3b), and the effects were attenuated by AMD3100.

The effect of CXCR4 siRNA on VEGFA mRNA and protein expression and HUVEC tube formation were similar to treatment with AMD3100, suggesting the effects of AMD3100 result from inhibition of CXCR4 signaling. CXCR4 siRNA efficiently knocked down CXCR4 expression (90% knockdown of mRNA) (Fig 4A, B), decreased VEGFA mRNA by 68% (Fig. 4A, p < 0.01), and VEGFA protein in conditioned medium by 51% (Fig. 4C, p < 0.02). Conditioned medium from JJ cells cultured in hypoxia after CXCR4 knockdown had 35% less effect on formation of HUVEC tube length (Fig. 4D, p < 0.01).

In order to determine if AMD3100 could be used as an antiangiogenic and antimetastatic agent in vivo, mice bearing xenograft tumors were treated with AMD3100. Bioimaging of xenograft tumors demonstrated AMD3100 decreased angiogenesis as measured by tumor content of AngioSense® probe. Probe content in treated tumors was decreased 56% compared to control (p < 0.03) (Fig. 5A–B). VEGFA content in treated tumors was decreased 45% of control (p < 0.002) (Fig. 5C). Representative immunohistochemical staining shows less CD31-positive microvessels within treated tumors (Fig. 5D). Final tumor weight and volume were decreased by 44% and 45% respectively (Fig. 6A,B) (p< 0.05). Evaluation of lungs demonstrated that AMD3100 treatment decreased the number of lung nodules by 56% (Fig. 6C) (p < 0.04).

Discussion
Chondrosarcoma is notable for its lack of response to systemic treatment and poor survival. Chemokines and their receptors regulate invasion, angiogenesis, migration, and metastasis. CXCR4 is the most common chemokine receptor expressed in cancer cells and upregulates factors related to invasiveness and angiogenesis. We therefore determined whether CXCR4 signaling contributes to VEGFA expression in chondrosarcoma and whether blocking CXCR4 would inhibit angiogenesis and metastasis in this tumor.

Regulation of VEGFA expression in chondrosarcoma, as in other tumors, involves a physiologic response to hypoxia and genetic aberrations found in tumors, with some overlap. VEGFA is directly upregulated by the transcription factor HIF1, which is increased during hypoxia as a result of decreased degradation (31). Here we show VEGFA is also upregulated by CXCR4 signaling in a positive feedback loop. The mechanisms of CXCR4 signaling include the MAP kinases ERK, JNK, and p38(36), which are known to upregulate VEGFA promoter activity (37). CXCR4 has been previously reported to be upregulated by VEGFA in normal endothelial cells and in breast cancer (26), however this is the first report of such upregulation in chondrosarcoma. CXCR4 is also upregulated by hypoxia via HIF1 (23). Therefore, there are multiple levels of regulation and amplification of VEGFA and CXCR4 expression. VEGFA expression is directly regulated by HIF1, which binds to the VEGFA promoter, and indirectly by CXCR4 signaling, which itself is increased by HIF1, VEGFA, and other factors such as PEA3, PAUF, PAX3-FKHR, nuclear respiratory factor 1, and estrogen (23;38;39). VEGFA receptors also signal through the MAP kinase and phosphatidylinositol 3-kinase pathways, which in turn upregulate CXCR4 (40). Our
results are consistent with investigations of transcriptional regulation of CXCR4 and VEGFA in other systems and emphasize the notion that any one factor can be regulated by multiple pathways. From a therapeutic standpoint, our data show inhibiting CXCR4 signaling can decrease VEGFA expression, albeit partially. This is important since directly inhibiting the effects of hypoxia on VEGFA expression is clinically not yet possible. Clinical translation will require a multipronged approach.

Inhibition of CXCR4 signaling also decreased the angiogenic phenotype in vitro and in vivo. In vitro, HUVEC tube formation and in vivo, bioimaging with AngioSense and microvessel count were all decreased by CXCR4 inhibition, consistent with the decreased expression and content of VEGFA in JJ cells and xenograft tumors. Bioimaging in other tumor systems, primarily carcinomas, using other antiangiogenic strategies have shown similar results. CXCR4 blockade with AMD3100, peptides, antibodies, or knockdown with siRNA has resulted in decreased tumor volume, angiogenesis, and lung metastases in xenograft mouse models of breast, prostate, and thyroid carcinoma and osteosarcoma (41-45). In prior work, we found AMD3100 inhibited hypoxia-induced invasion and expression of MMP1 in vitro, an important negative prognosticator in chondrosarcoma(11;23). Our current data suggest systemic administration of AMD3100 to tumor-bearing mice also inhibited tumor angiogenesis and VEGFA content in xenograft tumors, so that blocking CXCR4 has multiple beneficial effects (23).

Antiangiogenic treatment as a stand-alone strategy has recently been called into question. Although knockdown of VEGFA with RNA interference downregulated CXCR4 and tumor growth and angiogenesis in a xenograft model of non-small cell lung carcinoma (46), in patients with rectal carcinoma, treatment with bevacizumab, an anti-VEGFA
antibody, upregulated CXCL12 and CXCR4 in tumors and plasma CXCL12 levels, which correlated with development of lung metastases. This suggests anti-VEGF monotherapy can be accompanied by compensatory mechanisms and blocking CXCR4 in addition to VEGFA will be important in combination therapy (47). There is also the notion that normalization of tumor vasculature with anti-VEGF treatment will increase the efficacy of conventional cytotoxic chemotherapy (48). AMD3100 is a drug approved for human use as a stem cell mobilizer whose mechanism of action is specific inhibition of CXCR4. The extent to which CXCR4 inhibition with AMD3100 or other molecules alone or as part of combination therapy as treatment for chondrosarcoma in humans needs to be evaluated.

In summary, our results show that VEGFA expression increases CXCR4 expression and that CXCR4 blockade inhibits VEGFA production, angiogenesis, and metastasis in vitro and in a mouse chondrosarcoma xenograft model.

Acknowledgments

We thank Joel Block, MD for the human chondrosarcoma cell line JJ. The authors thank Virginia Hovanesian for assistance with image analysis of lungs.

Grant Support Section

One or more of the authors have received funding from the National Institutes of Health and from the National Center for Research Resources, a component of NIH: R.M.Terek, Q. Chen (Grant 1P20RR024484-01 and 9P20GM104937-06), L. Wei (Grant R01AR059142), W. Yang (Grant R21AR57156).

Reference List


(22) Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel


Figure Legends

Figure 1. CXCR4 expression is increased in xenograft chondrosarcoma tumors.

CXCR4 expression was evaluated with real-time PCR with normalization to 18S (A) and Western blot (B) as described in Materials and Methods. CH: chondrocytes, JJ: chondrosarcoma cell line, n: normoxia; h: hypoxia (2% O2); JJ-tumor: xenograft tumor. Levels of mRNA are shown as mean ± SD for 3 replicate determinations, * p < 0.001 compared to CH-n.

Figure 2. Effects of SDF-1 on VEGFA expression and VEGFA on CXCR4 expression. VEGFA (A) and CXCR4 (B) mRNA were quantified with real-time PCR in JJ cells cultured in normoxia after exposure to CXCL12 (10 ng/mL) or VEGFA (10 ng/mL) respectively. Levels of mRNA are shown as mean ± SD for 3 replicate determinations, *, p<0.03; #, p<0.02.

Figure 3. CXCR4 blockade decreases VEGFA expression and in vitro angiogenesis.

JJ cells were cultured in hypoxia with CXCL12 (10 ng/mL), AMD3100 (5 µg/mL), or both. (A) VEGFA in media was measured with ELISA. Data are shown as mean ± SD for three replicates. (B) HUVEC were cultured with conditioned media from JJ cells and total length of tubular structures measured after twenty-four hrs. Data are shown as mean ± SD. *,# p<0.001, CXCL12 compared to control, AMD3100 or AMD3100 plus CXCL12 compared to CXCL12 alone.

Figure 4. CXCR4 knockdown reduces VEGFA expression and in vitro angiogenesis.

JJ cells were cultured in hypoxia after transfection with CXCR4 siRNA or control siRNA. (A) VEGFA and CXCR4 mRNA were quantified relative to 18S with real-time PCR as described in Material and Methods. (B) CXCR4 was evaluated with Western
blot and VEGFA in conditioned media with ELISA (C). (D) HUVEC were cultured with conditioned media from JJ cells and length of tubular structures measured after twenty-four hrs. (E, F) Representative bright field images are shown. Data are shown as mean ± SD for three replicates (A,C) and four replicates (D). * < 0.01, # p < 0.0001; ** p < 0.02. Scale bar, 100 µm. Con-si: control siRNA, CXCR4-si: CXCR4 siRNA.

**Figure 5. AMD3100 decreases angiogenesis in xenograft tumors.**

(A) Representative Fluorescence-based Quantitative Tomography images performed with AngioSense probe are shown. (B) AngioSense content in xenograft tumors was measured after three weeks of treatment with AMD3100, N = 8/group. * p< 0.03. (C) VEGFA expression in xenograft tumor lysates was quantified with ELISA after four weeks of treatment, N = 8/group. *, p < 0.002. (D) Representative immunohistochemical analysis for CD31 positive microvessels in tumors are shown. 200×, bar = 100µm.

**Figure 6. AMD3100 decreases tumor weight, volume, and metastasis.**

Tumor volume (A), tumor weight (B), and number of lung nodules are shown after four weeks of treatment. N=8/group, *, p<0.05. #, p<0.04, Mann-Whitney U test, one-tail.
Fig. 1.
Fig. 2
**Fig. 3**

**A**

VEGF (pg/mL)

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>CXCL12</th>
<th>AMD</th>
<th>AMD+CXCL12</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean ± SD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGF (pg/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**B**

Length of tubular structures (µm)

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>CXCL12</th>
<th>AMD</th>
<th>AMD+CXCL12</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean ± SD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length of tubular structures (µm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Fig. 4.
Fig. 5.
Fig. 6.
Molecular Cancer Therapeutics

CXCR4-targeted Therapy Inhibits VEGF Expression and Chondrosarcoma Angiogenesis and Metastasis

Xiaojuan Sun, Cherie Charbonneau, Lei Wei, et al.

Mol Cancer Ther Published OnlineFirst May 17, 2013.

Updated version

Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-12-1092

Author Manuscript

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.